Oberadilol

Oberadilol
Nazivi
	Preferisani IUPAC naziv 4-hloro-2-[2-hidroksi-3-[[2-metil-1-[4-(4-metil-6-oksi-4,5-dihidro-1H-piridazin-3-il)anilino]propan-2-il]amino]propoksi]benzonitril
	Drugi nazivi 114856-44-9; 7ZNX9ET039; DTXSID2048745; OBERADILOL MONOETHYL MALEATE; UNII-7ZNX9ET039; SCHEMBL8813275; CHEMBL2105183; DTXCID9028671; Tox21_113202; NCGC00249416-01; CAS-114856-44-9; L001360; Q27269078
Identifikacija
CAS broj	114856-44-9 ;
3D model (Jmol)	interaktivna slika;
PubChem C ID	3047798;
UNII	7ZNX9ET039 ;
	SMILES CC1CC(=O)NN=C1C2=CC=C(C=C2)NCC(C)(C)NCC(COC3=C(C=CC(=C3)Cl)C#N)O; ; ; ; ; ;
Svojstva
Hemijska formula	C25H30ClN5O3
Molarna masa	484,00 g·mol−1
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	Reference infokutije

Oberadilol je agonist beta adrenergičkog receptora.^[3]

Reference[уреди | уреди извор]

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Mark J. Henderson; Kathleen A. Trychta; Shyh-Ming Yang; Yun Wang; Anton Simeonov; Brandon K. Harvey (2021). „A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome”. Cell Reports. doi:10.1016/j.celrep.2021.109040.